Typical T2Candida Panel testing population
In order to maximize the benefit of the T2Candida Panel, it is important to identify the optimal patients to test. Typically, symptomatic high-risk patients will be the primary population for testing. Common high-risk patient populations include those listed below. These patients would be symptomatic, immunocompromised and/or have conditions that require care in the ICU.
- Cancer / Chemotherapy
- BMT / HSCT, Liquid Transplant
- Solid Organ Transplant
- General ICU
T2Candida direcT2 pivotal trial
The annual number of high-risk admissions within a single 500-bed hospital is approximately 5,000 patients1. Here is the breakdown between immunocompromised and critical care patients in the T2Candida Panel pivotal trial:
|T2Candida Pivotal Trial Demographics|
|Medical History||Number of Patients|
|Solid Organ||171 (56.7%)|
|Critical Care & Related Conditions||781 (52.0%)|
NOTE: Immunocompromised patient percentages do not add up to 100% due to patients having multiple conditions.